ABSTRACT
BACKGROUND AND AIMS: Despite the availability of highly effective direct-acting antiviral therapy, chronic hepatitis C (CHC) continues to cause a major public health burden. In many high-income countries, treatment rates have been declining, which was exacerbated by the impact of the COVID-19 pandemic, threatening the ability to meet the World Health Organization (WHO)'s targets for eliminating HCV as a public health threat by 2030. We sought to model the impact of CHC in Canada, a resource-rich country with ongoing immigration from HCV-endemic regions; which relies exclusively on risk-based screening for case identification. APPROACH AND RESULTS: We developed an agent-based model to characterize the HCV epidemic in a high-income country with ongoing immigration. Combinations of prevention such as harm reduction, screening, and treatment strategies were considered. Model parameters were estimated from the literature and calibrated against historical HCV data. Sensitivity analyses were performed to assess uncertainty. Under the current status quo of risk-based screening, we predict the incidence of CHC-induced decompensated cirrhosis, HCC, and liver-related deaths would decrease by 79.4%, 76.1%, and 62.1%, respectively, between 2015 and 2030, but CHC incidence would only decrease by 11.1%. The results were sensitive to HCV transmission rate and an annual number of people initiating treatment. CONCLUSIONS: Current risk-based screening, and subsequent treatment, will be inadequate to achieve WHO goals. With extensive scale-up in screening, and treatment, the mortality target may be achievable, but the target for preventing new CHC cases is unlikely reachable, highlighting the importance of developing enhanced harm-reduction strategies for HCV elimination.
Subject(s)
Antiviral Agents , Feasibility Studies , Hepatitis C, Chronic , Mass Screening , Humans , Mass Screening/methods , Antiviral Agents/therapeutic use , Canada/epidemiology , Hepatitis C, Chronic/diagnosis , Hepatitis C, Chronic/epidemiology , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/prevention & control , COVID-19/epidemiology , COVID-19/prevention & control , Developed Countries/statistics & numerical data , Disease Eradication/methods , Female , Male , Incidence , SARS-CoV-2 , Middle Aged , AdultABSTRACT
BACKGROUND: Patients with chronic hepatitis C (CHC) can be cured with the new highly effective interferon-free combination treatments (DAA) that were approved in 2014. However, CHC is a largely silent disease, and many individuals are unaware of their infections until the late stages of the disease. The impact of wider access to effective treatments and improved awareness of the disease on the number of infections and the number of patients who remain undiagnosed is not known in Canada. Such evidence can guide the development of strategies and interventions to reduce the burden of CHC and meet World Health Organization's (WHO) 2030 elimination targets. The purpose of this study is to use a back-calculation framework informed by provincial population-level health administrative data to estimate the prevalence of CHC and the proportion of cases that remain undiagnosed in the three most populated provinces in Canada: British Columbia (BC), Ontario and Quebec. METHODS: We have conducted a population-based retrospective analysis of health administrative data for the three provinces to generate the annual incidence of newly diagnosed CHC cases, decompensated cirrhosis (DC), hepatocellular carcinoma (HCC) and HCV treatment initiations. For each province, the data were stratified in three birth cohorts: individuals born prior to 1945, individuals born between 1945 and 1965 and individuals born after 1965. We used a back-calculation modelling approach to estimate prevalence and the undiagnosed proportion of CHC. The historical prevalence of CHC was inferred through a calibration process based on a Bayesian Markov chain Monte Carlo (MCMC) algorithm. The algorithm constructs the historical prevalence of CHC for each cohort by comparing the model-generated outcomes of the annual incidence of the CHC-related health events against the data set of observed diagnosed cases generated in the retrospective analysis. RESULTS: The results show a decreasing trend in both CHC prevalence and undiagnosed proportion in BC, Ontario and Quebec. In 2018, CHC prevalence was estimated to be 1.23% (95% CI: .96%-1.62%), .91% (95% CI: .82%-1.04%) and .57% (95% CI: .51%-.64%) in BC, Ontario and Quebec respectively. The CHC undiagnosed proportion was assessed to be 35.44% (95% CI: 27.07%-45.83%), 34.28% (95% CI: 26.74%-41.62%) and 46.32% (95% CI: 37.85%-52.80%) in BC, Ontario and Quebec, respectively, in 2018. Also, since the introduction of new DAA treatment in 2014, CHC prevalence decreased from 1.39% to 1.23%, .97% to .91% and .65% to .57% in BC, Ontario and Quebec respectively. Similarly, the CHC undiagnosed proportion decreased from 38.78% to 35.44%, 38.70% to 34.28% and 47.54% to 46.32% in BC, Ontario and Quebec, respectively, from 2014 to 2018. CONCLUSIONS: We estimated that the CHC prevalence and undiagnosed proportion have declined for all three provinces since the new DAA treatment has been approved in 2014. Yet, our findings show that a significant proportion of HCV cases remain undiagnosed across all provinces highlighting the need to increase investment in screening. Our findings provide essential evidence to guide decisions about current and future HCV strategies and help achieve the WHO goal of eliminating hepatitis C in Canada by 2030.
Subject(s)
Antiviral Agents , Carcinoma, Hepatocellular , Hepatitis C, Chronic , Humans , Hepatitis C, Chronic/epidemiology , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/diagnosis , Antiviral Agents/therapeutic use , Prevalence , Male , Female , Retrospective Studies , Middle Aged , Carcinoma, Hepatocellular/epidemiology , Aged , Adult , Quebec/epidemiology , Ontario/epidemiology , Liver Neoplasms/epidemiology , British Columbia/epidemiology , Liver Cirrhosis/epidemiology , IncidenceABSTRACT
BACKGROUND: HCV elimination requires a thorough understanding of the care cascade. A direct-acting antiviral (DAA)-era description of the care cascade has not been undertaken in Ontario, Canada's most populous jurisdiction. Our primary objective was to describe the current population-level care cascade in the general Ontario population and among key risk groups â baby boomers, immigrants, and individuals experiencing residential instability. The secondary objective was to identify predictors of engagement. METHODS: We conducted a population-based cohort study of Ontario residents undergoing HCV testing between January 1, 1999, and December 31, 2018, and mapped the care cascade [antibody-diagnosed, RNA tested, RNA positive, genotyped, treated, achieved sustained virologic response, reinfected/relapsed] as of December 31, 2018. The cascade was stratified by risk groups. Cause-specific hazard modeling was used to identify demographic, and socioeconomic predictors of engagement with key steps of the cascade. RESULTS: Among 108,428 Ontario residents living with an HCV antibody diagnosis, 88% received confirmatory RNA testing; of these, 62% tested positive and 94% of positive tests were genotyped. Of those with confirmed viremia, 53% initiated treatment and 76% of treated individuals achieved sustained virologic response, while ~1% experienced reinfection or relapse. Males, older birth cohorts, long-term residents, those with a history of substance use disorder and social marginalization (eg, material deprivation, residential instability), and those initially diagnosed in the pre-DAA era exhibited lower rates of engagement with almost every step of HCV care. CONCLUSIONS: Despite DAA era improvements, treatment initiation remains a major gap. HCV screening and linkage-to-treatment, particularly for those with a history of substance use disorder and social marginalization, will be needed to equitably close gaps in HCV care in the province.
Subject(s)
Hepatitis C, Chronic , Substance-Related Disorders , Male , Humans , Antiviral Agents/therapeutic use , Cohort Studies , Hepatitis C, Chronic/drug therapy , Neoplasm Recurrence, Local , RNA, ViralABSTRACT
The tumor control probability (TCP) is a metric used to calculate the probability of controlling or eradicating tumors through radiotherapy. Cancer cells vary in their response to radiation, and although many factors are involved, the tumor microenvironment is a crucial one that determines radiation efficacy. The tumor microenvironment plays a significant role in cancer initiation and propagation, as well as in treatment outcome. We have developed stochastic formulations to study the impact of arbitrary microenvironmental fluctuations on TCP and extinction probability (EP), which is defined as the probability of cancer cells removal in the absence of treatment. Since the derivation of analytical solutions are not possible for complicated cases, we employ a modified Gillespie algorithm to analyze TCP and EP, considering the random variations in cellular proliferation and death rates. Our results show that increasing the standard deviation in kinetic rates initially enhances the probability of tumor eradication. However, if the EP does not reach a probability of 1, the increase in the standard deviation subsequently has a negative impact on probability of cancer cells removal, decreasing the EP over time. The greatest effect on EP has been observed when both birth and death rates are being randomly modified and are anticorrelated. In addition, similar results are observed for TCP, where radiotherapy is included, indicating that increasing the standard deviation in kinetic rates at first enhances the probability of tumor eradication. But, it has a negative impact on treatment effectiveness if the TCP does not reach a probability of 1.
Subject(s)
Neoplasms , Algorithms , Humans , Neoplasms/therapy , Probability , Tumor MicroenvironmentABSTRACT
The tumour control probability (TCP) is a treatment planning tool that evaluates the probability of tumour eradication and helps in the assessment of the relative efficacy of different radiotherapy regimens. The response of tumours to radiation differs greatly even between patients with same types of cancers. Tumour heterogeneity or cellular diversity among cancer cells has a pronounced impact on the success of administered radiotherapy protocols. Tumour heterogeneity can be explained using the cancer stem cells (CSCs) hypothesis, which posits that CSCs are responsible for tumour initiation and propagation as well as therapeutic resistance. Moreover, the existence of plasticity or bidirectional transition between CSCs and non-CSCs indicates that, sometimes, non-CSCs appear to mimic CSC phenotypes, resulting in an increase in resistance. Here, we have developed a stochastic model to investigate the impact of plasticity on the efficacy of radiotherapy. The effect of plasticity on TCP is explored by applying the model to standard and hyper-fractionated schedules for a three week period of treatment as well as standard, hyper-fractionated, and accelerated hyper-fractionated schedules with an equal total dose of 30 Gy. Our results confirm that tumour control becomes increasingly difficult in the presence of plasticity as well as for the most resistant tumours. For the case with equal total dose, it is observed that increasing fractionation, at first enhances the probability of CSCs and tumour removal, but ultimately results in lower TCPS+P and TCPS. In addition, the combination of radiotherapy and targeted therapy (with increasing CSC differentiation) improves both the probability of CSC and tumour removal, in the absence of plasticity. However, in the presence of plasticity, the impact of combination therapy is not significant.
Subject(s)
Cell Plasticity , Neoplasms , Dose Fractionation, Radiation , Humans , Neoplasms/therapy , Neoplastic Stem Cells , ProbabilityABSTRACT
Radiotherapy uses high doses of energy to eradicate cancer cells and control tumors. Various treatment schedules have been developed and tried in clinical trials, yet significant obstacles remain to improving the radiotherapy fractionation. Genetic and non-genetic cellular diversity within tumors can lead to different radiosensitivity among cancer cells that can affect radiation treatment outcome. We propose a minimal mathematical model to study the effect of tumor heterogeneity and repair in different radiation treatment schedules. We perform stochastic and deterministic simulations to estimate model parameters using available experimental data. Our results suggest that gross tumor volume reduction is insufficient to control the disease if a fraction of radioresistant cells survives therapy. If cure cannot be achieved, protocols should balance volume reduction with minimal selection for radioresistant cells. We show that the most efficient treatment schedule is dependent on biology and model parameter values and, therefore, emphasize the need for careful tumor-specific model calibration before clinically actionable conclusions can be drawn.
Subject(s)
Models, Biological , Neoplasms/radiotherapy , Breast Neoplasms/radiotherapy , Computer Simulation , DNA Damage , Dose Fractionation, Radiation , Female , Humans , Mathematical Concepts , Radiation Tolerance , Stochastic ProcessesABSTRACT
A new deterministic model for assessing the role of age-structure on the transmission dynamics of malaria in a community is designed. Rigorous qualitative analysis of the model reveals that it undergoes the phenomenon of backward bifurcation, where the stable disease-free equilibrium of the model co-exists with a stable endemic equilibrium when the associated reproduction number (denoted by R0) is less than unity. It is shown that the backward bifurcation phenomenon is caused by the malaria-induced mortality in humans. A special case of the model is shown to have a unique endemic equilibrium whenever the associated reproduction threshold exceeds unity. Further analyses reveal that adding age-structure to a basic model for malaria transmission in a community does not alter the qualitative dynamics of the basic model, with respect to the existence and asymptotic stability of the associated equilibria and the backward bifurcation property of the model. Numerical simulations of the model show that the cumulative number of new cases of infection and malaria-induced mortality increase with increasing average lifespan and birth rate of mosquitoes.